Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men

Jed P. Weber, Patrick C. Walsh, Craig A Peters, Jerry L. Spivak

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

To examine the role of testosterone in the maintenance of hemoglobin levels, we studied the effect of reversible androgen deprivation on hemoglobin, serum immunoreactive erythropoietin, and serum testosterone in seven men treated with a luteinizing hormone‐releasing factor (LHRH) agonist for 6 months and then followed for an additional 6 months. The mean serum testosterone level was 4.35 ± 1.05 ng/ml initially and it decreased to castrate levels in all patients by 6 months. After stopping therapy, there was a rapid increase in serum testosterone such that by 12 months the mean concentration was normal. The pretreatment hemoglobin was 15.2 ± 0.9 g/dl (mean ± SD); after 6 months of androgen deprivation it had fallen to 14.1 ± 0.4 g/dl (P < 0.05). Six months after stopping therapy, the hemoglobin rose to pre‐treatment levels. Before treatment, serum immunoreactive erythropoietin was 9.5 ± 4.6 mu/ml (mean ± SD) and did not change significantly during or after the 6 month period of androgen deprivation. No significant inhibition of burst‐forming unit‐erythroid (BFU‐E) or colony‐forming unit‐granulocyte macrophage (CFU‐GM) was observed at the serum levels of nafarelin acetate obtainable in vivo. These data suggest that, within the normal range of hemoglobin in men, androgens are a determinant of the red cell mass.

Original languageEnglish (US)
Pages (from-to)190-194
Number of pages5
JournalAmerican Journal of Hematology
Volume36
Issue number3
DOIs
StatePublished - Jan 1 1991

Fingerprint

Erythropoietin
Androgens
Hemoglobins
Testosterone
Serum
Nafarelin
Erythrocyte Volume
Gonadotropin-Releasing Hormone
Reference Values
Therapeutics
Macrophages
Maintenance

Keywords

  • erythropoiesis
  • LHRH agonist
  • testosterone

ASJC Scopus subject areas

  • Hematology

Cite this

Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. / Weber, Jed P.; Walsh, Patrick C.; Peters, Craig A; Spivak, Jerry L.

In: American Journal of Hematology, Vol. 36, No. 3, 01.01.1991, p. 190-194.

Research output: Contribution to journalArticle

@article{dc4236f670ea4900a956e6988f0e6ce9,
title = "Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men",
abstract = "To examine the role of testosterone in the maintenance of hemoglobin levels, we studied the effect of reversible androgen deprivation on hemoglobin, serum immunoreactive erythropoietin, and serum testosterone in seven men treated with a luteinizing hormone‐releasing factor (LHRH) agonist for 6 months and then followed for an additional 6 months. The mean serum testosterone level was 4.35 ± 1.05 ng/ml initially and it decreased to castrate levels in all patients by 6 months. After stopping therapy, there was a rapid increase in serum testosterone such that by 12 months the mean concentration was normal. The pretreatment hemoglobin was 15.2 ± 0.9 g/dl (mean ± SD); after 6 months of androgen deprivation it had fallen to 14.1 ± 0.4 g/dl (P < 0.05). Six months after stopping therapy, the hemoglobin rose to pre‐treatment levels. Before treatment, serum immunoreactive erythropoietin was 9.5 ± 4.6 mu/ml (mean ± SD) and did not change significantly during or after the 6 month period of androgen deprivation. No significant inhibition of burst‐forming unit‐erythroid (BFU‐E) or colony‐forming unit‐granulocyte macrophage (CFU‐GM) was observed at the serum levels of nafarelin acetate obtainable in vivo. These data suggest that, within the normal range of hemoglobin in men, androgens are a determinant of the red cell mass.",
keywords = "erythropoiesis, LHRH agonist, testosterone",
author = "Weber, {Jed P.} and Walsh, {Patrick C.} and Peters, {Craig A} and Spivak, {Jerry L.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1002/ajh.2830360306",
language = "English (US)",
volume = "36",
pages = "190--194",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men

AU - Weber, Jed P.

AU - Walsh, Patrick C.

AU - Peters, Craig A

AU - Spivak, Jerry L.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - To examine the role of testosterone in the maintenance of hemoglobin levels, we studied the effect of reversible androgen deprivation on hemoglobin, serum immunoreactive erythropoietin, and serum testosterone in seven men treated with a luteinizing hormone‐releasing factor (LHRH) agonist for 6 months and then followed for an additional 6 months. The mean serum testosterone level was 4.35 ± 1.05 ng/ml initially and it decreased to castrate levels in all patients by 6 months. After stopping therapy, there was a rapid increase in serum testosterone such that by 12 months the mean concentration was normal. The pretreatment hemoglobin was 15.2 ± 0.9 g/dl (mean ± SD); after 6 months of androgen deprivation it had fallen to 14.1 ± 0.4 g/dl (P < 0.05). Six months after stopping therapy, the hemoglobin rose to pre‐treatment levels. Before treatment, serum immunoreactive erythropoietin was 9.5 ± 4.6 mu/ml (mean ± SD) and did not change significantly during or after the 6 month period of androgen deprivation. No significant inhibition of burst‐forming unit‐erythroid (BFU‐E) or colony‐forming unit‐granulocyte macrophage (CFU‐GM) was observed at the serum levels of nafarelin acetate obtainable in vivo. These data suggest that, within the normal range of hemoglobin in men, androgens are a determinant of the red cell mass.

AB - To examine the role of testosterone in the maintenance of hemoglobin levels, we studied the effect of reversible androgen deprivation on hemoglobin, serum immunoreactive erythropoietin, and serum testosterone in seven men treated with a luteinizing hormone‐releasing factor (LHRH) agonist for 6 months and then followed for an additional 6 months. The mean serum testosterone level was 4.35 ± 1.05 ng/ml initially and it decreased to castrate levels in all patients by 6 months. After stopping therapy, there was a rapid increase in serum testosterone such that by 12 months the mean concentration was normal. The pretreatment hemoglobin was 15.2 ± 0.9 g/dl (mean ± SD); after 6 months of androgen deprivation it had fallen to 14.1 ± 0.4 g/dl (P < 0.05). Six months after stopping therapy, the hemoglobin rose to pre‐treatment levels. Before treatment, serum immunoreactive erythropoietin was 9.5 ± 4.6 mu/ml (mean ± SD) and did not change significantly during or after the 6 month period of androgen deprivation. No significant inhibition of burst‐forming unit‐erythroid (BFU‐E) or colony‐forming unit‐granulocyte macrophage (CFU‐GM) was observed at the serum levels of nafarelin acetate obtainable in vivo. These data suggest that, within the normal range of hemoglobin in men, androgens are a determinant of the red cell mass.

KW - erythropoiesis

KW - LHRH agonist

KW - testosterone

UR - http://www.scopus.com/inward/record.url?scp=0026102045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026102045&partnerID=8YFLogxK

U2 - 10.1002/ajh.2830360306

DO - 10.1002/ajh.2830360306

M3 - Article

C2 - 1705094

AN - SCOPUS:0026102045

VL - 36

SP - 190

EP - 194

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -